Excessive anticoagulation in patients with mild renal insufficiency receiving long‐term therapeutic enoxaparin
- 22 March 2001
- journal article
- case report
- Published by Wiley in American Journal of Hematology
- Vol. 67 (1) , 54-56
- https://doi.org/10.1002/ajh.1077
Abstract
Low‐molecular‐weight heparins, such as enoxaparin, are increasingly being used for treatment of venous thromboembolism. We describe two patients who received therapeutic enoxaparin for several months. Although their serum creatinine values were normal, both had mild renal insufficiency (creatinine clearance 60–70 ml/min), and both accumulated the drug abnormally and experienced clinical bleeding. These results suggest that patients receiving enoxaparin (or other low‐molecular‐weight heparins) in therapeutic doses for periods of more than 4 weeks should be considered for laboratory monitoring to avoid bleeding. Am. J. Hematol. 67:54–56, 2001.Keywords
This publication has 8 references indexed in Scilit:
- Subcutaneous Enoxaparin Once or Twice Daily Compared with Intravenous Unfractionated Heparin for Treatment of Venous Thromboembolic DiseaseAnnals of Internal Medicine, 2001
- Outpatient treatment of deep vein thrombosis: translating clinical trials into practiceThe American Journal of Medicine, 1999
- Antithrombotic Therapy for Venous Thromboembolic DiseaseChest, 1998
- Treatment of Proximal Vein Thrombosis With Subcutaneous Low-Molecular-Weight Heparin vs Intravenous HeparinArchives of internal medicine (1960), 1997
- A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein ThrombosisNew England Journal of Medicine, 1996
- EnoxaparinDrugs, 1992
- Low molecular weight heparinBlood, 1992
- Delayed elimination of enoxaparine in patients with chronic renal insufficiencyThrombosis Research, 1991